Semmola-Meryon-Duchenne syndrome

There is no satisfactory therapy for many of the disabling genetic disorders such as Semmola-Meryon-Duchenne syndrome. However, it is hoped that advances arising from the accumulating research evidence can contribute to improving treatment of such conditions. Therefore, reviewing the literature for the recent research evidence is recommended to improve the therapeutic services for patients with such disorders. The occurrence of Semmola-Meryon-Duchenne syndrome in Iraq has not been documented. In addition to providing the historical documentation of this syndrome, particularly the early history of its documentation, this book describes the occurrence of Semmola-Meryon-Duchenne syndrome in two Iraqi brothers. This book also reviews the available research evidence which may contribute to improving its treatment.

Autorentext

Professor Aamir Jalal Al Mosawi, is senior advisor doctor at Baghdad Medical City. He is the Head of Iraq Headquarter of Copernicus Scientists International Panel. He is member of the American Academy of Pediatrics. He served as a member of the advisory council the International Association of Medical Colleges (IAMC).